Author(s)

Antonin Wilson Ndjitoyap Ndam^1*, Alpha Hamed Béchir Ndam Mefire¹, Winnie Bekolo², Guy Roger Nsenga Djapa³, Suzanne Ngo Um Sap⁴, Paul Koki Ndombo⁴, Elie Claude Ndjitoyap Ndam¹

¹Department of Internal Medicine and Specialities, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
²Department of Clinical Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.
³Department of Internal Medicine and Specialities, Faculty of Medicine and Biomedical Sciences, University of Dschang, Dschang, Cameroun.
⁴Department of Paediatrics, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.

Background: the hepatitis B virus infection remains a major public health problem worldwide. It can lead to a liver cirrhosis and/or hepatocellular carcinoma. The World Health Organisation (WHO) has recommended the implementation of generalised vaccination programs against hepatitis B. In Cameroon, this vaccine was introduced in the expanded program on immunization (EPI) in 2005, but few studies have assessed the immune response. Objective: the general objective of this study was to identify factors associated with antibody levels among children aged from 15 to 59 months vaccinated against hepatitis B during the EPI in Cameroon. Method: this was a cross-sectional study carried out from December 2021 to June 2022 in a paediatric centre of Yaoundé (Cameroon). We analysed the antibody level in children vaccinated against hepatitis B within the framework of the EPI. We enrolled children who had received a series of 3 intramuscular doses of hepatitis B vaccine at 6, 10 and 14 weeks after birth. Some children could receive a 4^th booster dose between 12 months. The antibody level was assessed by measuring the anti-HBs in such children, aged 15 - 59 months. A good immunization was defined as a serum level of anti-HBs antibody level above 100 IU/mL; a poor immunization, for an anti-HBs antibody level between 10 and 100 IU/mL; and a non-immunization, for an anti-HBs antibody level < 10 IU/mL. Association between explored factors and poor or non-immunization was evaluated through the Chi square test. The significance threshold was defined at p < 0.05. Results: sixty subjects were included in the study with a slight female majority: 31 cases (52%). The average age was 38.5 ± 15.7 months (range 15 - 59 months). We found 32 (53%) cases of good immunization; 21 (35%) of poor immunization; and 7 children (12%) with a non-immunization. The only factor associated with poor or non-immunization was the age between 37 - 59 months (p = 0.016). Conclusion: Anti HBs Antibody levels in children vaccinated against hepatitis B virus were globally satisfactory in our series. Results show an association between low antibody levels with older age (over 36 months), suggesting a circulating antibodies levels decrease over time, yet deemed protecting until 59 months.

Hepatitis B, Vaccination, Children, Antibody Levels, Immunization, Cameroon

Ndjitoyap Ndam, A. , Ndam Mefire, A. , Bekolo, W. , Nsenga Djapa, G. , Ngo Um Sap, S. , Koki Ndombo, P. and Ndjitoyap Ndam, E. (2023) Factors Associated with Antibody Levels among Children Aged 15 to 59 Months Vaccinated against Hepatitis B during the Expanded Program on Immunization in Cameroon. Open Journal of Gastroenterology, 13, 91-98. doi: 10.4236/ojgas.2023.132010.